MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.leukres.2015.12.007

Медицинская библиотека · Leukemia research · 2015

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.

Nazha Aziz, Sekeres Mikkael A, Garcia-Manero Guillermo, Barnard John, Al Ali Najla H, Roboz Gail J, Steensma David P, DeZern Amy E, Zimmerman Cassie, Jabbour Elias J, Zell Katrina, List Alan F, Kantarjian Hagop M, Maciejewski Jaroslaw P, Komrokji Rami S, MDS Clinical Research Consortium

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Treatment with hypomethylating agents (HMAs) improves overall survival (OS) in patients who achieve a response of stable disease (SD) or better (complete remission [CR], partial remission [PR], or hematologic improvement [HI]). It is not well established if patients who achieve SD at 4-6 months of therapy should be offered different therapies to optimize their response or continue with the same regimen. Clinical data were obtained from the MDS Clinical Research Consortium database. SD was defined as no evidence of progression and without achievement of any other responses. Of 291 patients treated with AZA or DAC, 55% achieved their best response (BR) at 4-6 months. Among patients with SD at 4-6 months, 29 (20%) achieved a better response at a later treatment time point. Younger patients with lower bone marrow blast percentages, and intermediate risk per IPSS-R were more likely to achieve a better response (CR, PR, or HI) after SD at 4-6 months. Patients with SD who subsequently achieved CR had superior OS compared to patients who remained with SD (28.1 vs. 14.4 months, respectively, p=.04). In conclusion, patients treated with HMAs who achieves CR after a SD status had longer survival with continuous treatment after 6 months.

Для цитирования: Nazha Aziz, Sekeres Mikkael A, Garcia-Manero Guillermo, Barnard John, Al Ali Najla H, Roboz Gail J, Steensma David P, DeZern Amy E, Zimmerman Cassie, Jabbour Elias J, Zell Katrina, List Alan F, Kantarjian Hagop M, Maciejewski Jaroslaw P, Komrokji Rami S, MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.. Leukemia research. 2015. DOI: 10.1016/j.leukres.2015.12.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.